Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.52 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.47 |
| ▸ | STAT3 | P40763 | 12/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | STAT1 | P42224 | 2/20 | 0.44 |
| ▸ | STAT5B | P51692 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15668511 | 0.87 | EGFR (0.53) | ACMSDSTAT3KDRHTR2CHTR2B | |
| SCHEMBL20400504 | 0.87 | KDM4C (0.50) | ACMSDKDM4CPPARASTING1STAT3 | |
| SCHEMBL22223983 | 0.83 | KDM4C (0.44) | ACMSDKDM4CPPARASTING1STAT3 | |
| SCHEMBL2647028 | 0.81 | HAO1 (0.52) | KDM4CKDRHTR2CHTR2B | |
| SCHEMBL20401144 | 0.80 | PPARA (0.47) | PPARAKDR | |
| SCHEMBL15668399 | 0.80 | EGFR (0.58) | ACMSDKDM4CPPARASTING1KDR | |
| SCHEMBL15215022 | 0.80 | KDR (0.47) | KDM4CKDRHTR2CHTR2B | |
| SCHEMBL13317165 | 0.79 | KDM4C (0.59) | KDM4CPPARASTING1 | |
| SCHEMBL7079654 | 0.79 | KDM4C (0.58) | KDM4CPPARASTING1 | |
| SCHEMBL27592888 | 0.78 | ACMSD (0.76) | ACMSDSTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150259366-A1 | STAT3 DIMERIZATION INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259366-A1 | STAT3 DIMERIZATION INHIBITORS | STAT3, JAK2, STAT1 | ACMSD 4768/4885KDM4C 3704/4885PPARA 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.